2-氯-4-三氟甲氧基苯硼酸 | 345226-20-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 2-氯-4-三氟甲氧基苯硼酸
• 中文别名: 2-氯-4-三氟甲氧基苯基硼酸
• 英文名称: (2-chloro-4-(trifluoromethoxy)phenyl)boronic acid
• 英文别名: [2-chloro-4-(trifluoromethoxy)phenyl]boronic acid
• CAS: 345226-20-2
• 化学式: C₇H₅BClF₃O₃
• 分子量: 240.374
• InChiKey: ISTQXKDCRJYPFJ-UHFFFAOYSA-N

物化性质

• 熔点：
  150-152 °C
• 沸点：
  294.1±50.0 °C(Predicted)
• 密度：
  1.53±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.92
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  49.7
• 氢给体数：
  2
• 氢受体数：
  6

安全信息

• 危险性防范说明：
  P261,P280,P301+P312,P302+P352,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  室温

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Chloro-4-trifluoromethoxyphenylboronic acid
Synonyms: 2-Chloro-4-(trifluoromethoxy)phenylboronic acid

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Chloro-4-trifluoromethoxyphenylboronic acid
CAS number: 345226-20-2

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H5BClF3O3
Molecular weight: 240.4

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen chloride, hydrogen fluoride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-氯-4-三氟甲氧基苯硼酸 在 bis-triphenylphosphine-palladium(II) chloride 、 barium dihydroxide 、 ammonium hydroxide 、 sodium sulfate 作用下， 以 1,4-二氧六环 、 乙二醇二甲醚 、 水 为溶剂， 反应 48.0h， 生成 4-(2-Chloro-4-trifluoromethoxy-phenyl)-2-ethyl-1-((S)-1-methyl-butyl)-1H-imidazo[4,5-c]pyridine
  参考文献：
  名称：

  Imidazo[4,5-b]pyridines as corticotropin releasing factor receptor ligands

  摘要：

  A series of high affinity CRF receptor ligands with an imidazo[4,5-b]pyridine core is described. Individual analogues were synthesized and tested in a rat CRF receptor binding assay. The best compounds were further tested in the dog N-in-1 pharmaco-kinetic model to assess plasma levels at 1 mg/kg (po) and in the rat situational anxiety model to assess anxiolytic efficacy at 3 mg/kg (po). The structure-activity relationships for good receptor binding affinity are described herein. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00833-8
• 作为产物：
  描述：

  2-氯-4-三氟甲氧基碘苯 在 正丁基锂 、 硼酸三异丙酯 、 盐酸 作用下， 以 四氢呋喃 、 正己烷 、 甲苯 、 水 为溶剂， 反应 7.17h， 以64%的产率得到2-氯-4-三氟甲氧基苯硼酸
  参考文献：
  名称：

  Synthesis and Structure−Activity Relationships of Aza- and Diazabiphenyl Analogues of the Antitubercular Drug (6S)-2-Nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824)

  摘要：

  New heterocyclic analogues of the potent biphenyl class derived from antitubercular drug PA-824 were prepared, aiming to improve aqueous solubility but maintain high metabolic stability and efficacy. The strategy involved replacement of one or both phenyl groups by pyridine, pyridazine, pyrazine, or pyrimidine, in order to reduce lipophilicity. For para-linked biaryls, hydrophilicities (ClogP) correlated with measured solubilities, but highly soluble bipyridine analogues displayed weak antitubercular activities. A terminal pyridine or proximal heterocycle allowed retention of potency and provided solubility improvements, particularly at low pH, with examples from the latter classes displaying the better in vivo efficacies, high metabolic stabilities, and excellent pharmacokinetics. Five such compounds were >100-fold better than the parent drug in a mouse model of acute Mycobacterium tuberculosis infection, and two orally bioavailable pyridine analogues (3-4-fold more soluble than the parent at low pH) were superior to antitubercular drug OPC-67683 in a chronic infection model.

  DOI：

  10.1021/jm101288t

文献信息

• Pyrazolyl-Based Carboxamides II
  申请人：Grünenthal GmbH

  公开号：US20140194452A1

  公开（公告）日：2014-07-10

  The invention relates to pyrazolyl-based carboxamide compounds useful as ICRAC inhibitors, to pharmaceutical compositions containing these compounds and to these compounds for the use in the treatment and/or prophylaxis of diseases and/or disorders, in particular inflammatory diseases and/or inflammatory disorders.

  这项发明涉及以吡唑基为基础的羧酰胺化合物，其作为ICRAC抑制剂有用，以及含有这些化合物的药物组合物，以及这些化合物在治疗和/或预防疾病和/或疾病中的用途，特别是炎症性疾病和/或炎症性疾病。
• Re-evaluating pretomanid analogues for Chagas disease: Hit-to-lead studies reveal both in vitro and in vivo trypanocidal efficacy
  作者：Andrew M. Thompson、Patrick D. O’Connor、Andrew J. Marshall、Amanda F. Francisco、John M. Kelly、Jennifer Riley、Kevin D. Read、Catherine J. Perez、Scott Cornwall、R.C. Andrew Thompson、Martine Keenan、Karen L. White、Susan A. Charman、Bilal Zulfiqar、Melissa L. Sykes、Vicky M. Avery、Eric Chatelain、William A. Denny

  DOI：10.1016/j.ejmech.2020.112849

  日期：2020.12

  foundation for a more in-depth assessment of the best leads, focusing on both drug-like attributes (solubility, metabolic stability and safety) and maximal killing of the parasite in a shorter timeframe. Comparative appraisal of one preferred lead (58) in a chronic infection mouse model, monitored by highly sensitive bioluminescence imaging, provided the first definitive evidence of (partial) curative

  表型筛选了900种抗结核硝基咪唑衍生物的化合物库，这些化合物与昆虫前体有关，与原生动物寄生虫克鲁斯锥虫（查加斯病的病原体）有关，鉴定了几种结构多样的命中，其作用方式未知。初步分析后，体内首次概念验证进行了一项研究，其中每天一次口服7-取代的2-硝基咪唑并恶嗪类似物可将血液寄生虫病抑制到低水平或无法检测到的水平，尽管无法实现无菌治愈。有限的命中扩增研究以及针对内脏利什曼病的新化合物的反筛选为更好地评估最佳潜在药物奠定了基础，重点关注类药物的特性（溶解性，代谢稳定性和安全性）以及最大杀伤力在较短的时间内寄生虫。通过高度敏感的生物发光成像监测，在慢性感染小鼠模型中对一种优选的铅（58）进行的比较评估，为这种有前途的硝基咪唑并恶嗪类化合物提供了（部分）疗效的首个确凿证据。
• [EN] PYRIDINO AND PYRIMIDINO PYRAZINONES FOR TREATMENT OF ANXIETY AND DEPRESSION<br/>[FR] PYRAZINONES PYRIDINO ET PYRIMIDINO DESTINEES AU TRAITEMENT DE L'ANXIETE ET DE LA DEPRESSION
  申请人：BRISTOL MYERS SQUIBB PHARMA CO

  公开号：WO2004031189A1

  公开（公告）日：2004-04-15

  The present invention provides compounds of Formula (I): wherein the variables A, B, Ar, R1, R2, and R3 are as defined herein. The compounds of Formula (I) can function as corticotropin releasing factor (CRF) receptor antagonists and can be useful, for example, in the treatment of disorders characterized by abnormal levels of CRF such as anxiety and depression.

  本发明提供了化合物的结构式（I）：其中变量A、B、Ar、R1、R2和R3的定义如本文所述。结构式（I）的化合物可以作为促肾上腺皮质激素释放因子（CRF）受体拮抗剂发挥作用，并且可以用于治疗由CRF异常水平引起的疾病，如焦虑和抑郁症。
• FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS
  申请人：Gilead Sciences, Inc.

  公开号：US20150175595A1

  公开（公告）日：2015-06-25

  The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: wherein n, R 1 , R 2 , R 2′ , R 3 , R 4 , R 5 , R 6 and R 7 are as described herein, and to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.

  本公开涉及的化合物是钠通道抑制剂，并用于治疗各种疾病状态，包括心血管疾病和糖尿病。在特定实施例中，化合物的结构由公式I给出：其中n，R1，R2，R2'，R3，R4，R5，R6和R7如本文所述，并提供了制备和使用该化合物以及含有该化合物的制药组合物的方法。
• [EN] N-(HYDROXYALKYL (HETERO)ARYL) TETRAHYDROFURAN CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS<br/>[FR] N-(HYDROXYALKYL (HÉTÉRO)ARYL) TÉTRAHYDROFURAN CARBOXAMIDES UTILISÉS EN TANT QUE MODULATEURS DE CANAUX SODIQUES
  申请人：VERTEX PHARMA

  公开号：WO2022256622A1

  公开（公告）日：2022-12-08

  Compounds of formula I and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided. Also provided are pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts and methods of using the compounds, pharmaceutically acceptable salts, and pharmaceutical compositions in the treatment of various disorders, including pain.

  提供了化学式I的化合物及其药学上可接受的盐，用作钠通道抑制剂。还提供了包含该化合物或药学上可接受的盐的制药组合物以及使用该化合物、药学上可接受的盐和制药组合物治疗各种疾病，包括疼痛的方法。